Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Breaching the Blood-Brain Barrier

By CLN Stat
Posted on 27 Jun 2018
A late-breaking session at the AACC 70th Annual Scientific Meeting & Clinical Lab Expo in Chicago will highlight the uses and implications of the first chemical biomarker test cleared by the U.S. More...
Food and Drug Administration for detecting mild traumatic brain injury (mTBI) or concussion. It will also examine other TBI biomarkers.

“TBI is a very large problem in both civilian and military occupations and activities,” session moderator Robert Christenson, PhD, professor of pathology and professor of medical and research technology at the University of Maryland School of Medicine in Baltimore, told CLN Stat. “Blood is a simple specimen to obtain, and a biomarker would be of great value for rapid rule-out or rule-in of TBI. This would be from economic and, most importantly, patient health reasons,” said Christenson, who is co-presenting with Frank Peacock, MD, professor of emergency medicine at Baylor College of Medicine in Houston, and Robert Welch, MD, director of clinical research at Wayne State University School of Medicine in Detroit.

In his presentation, Christenson plans to cover the interpretation of brain biomarker tests. The speakers also will describe the characteristics of an ideal TBI marker, as well as the evidence for proposed biomarkers that have already been explored. Another discussion will address the seminal trial of the newly cleared test, called Brain Trauma Indicator (BTI), and detail how BTI might be used in emergency department settings.

Detecting TBI in blood is not without its challenges, Christenson emphasized. A blood-brain barrier exists between the blood compartment and the brain compartment. “To determine what brain-specific biomarkers are of high enough concentration to leak over to the blood compartment and be detected in a reasonable time frame after injury has been challenging. There are both biological and technical measurement considerations,” he said.

Clinical laboratorians from all aspects of testing and reimbursement need to understand the inner workings of brain biomarkers, and in particular what the BTI test is—and what it’s not, Christenson indicated. “Interpretation of the test results will also be critical for laboratorians to know, as they will be asked questions about test results by clinicians,” he added.

Participants of this session will be able to:

1. Identify strategies for identifying, quantifying, and validating potential TBI biomarkers;
2. Discuss the algorithm for interpreting the Brain Trauma Index; and
3. List ways that TBI biomarkers can benefit patients and decrease healthcare costs.

Register now for the AACC 70th Annual Scientific Meeting & Clinical Lab Expo in Chicago to attend this informative session on August 2. Attendees will receive 1.5 CE hours.



Visit AACC 2018 >>



New
Gold Member
Immunochromatographic Assay
CRYPTO Cassette
Portable Electronic Pipette
Mini 96
New
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
New
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Dormant tumor cells evade imaging tests and may later reactivate to spread metastatic breast cancer (Photo courtesy of David A. Litman/Shutterstock)

MRD Testing Can Identify Breast Cancer Survivors at Higher Risk of Recurrence

Breast cancer survival rates continue to improve, but recurrence remains incurable and affects around 30% of patients. Some subtypes, like triple negative and HER2+, relapse within years, while ER+ cancers... Read more

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.